| DIRECT COMPETITOR COMPARISON | |
| ROSG | ALNY | ISIS | MRK | Industry | | Market Cap: | 27.50M | 730.93M | 977.90M | 78.88B | 47.35M | | Employees: | N/A | 175 | 300 | 55,200 | 56 | | Qtrly Rev Growth (yoy): | N/A | -5.80% | -9.10% | 1.80% | 18.90% | | Revenue (ttm): | 1.54M | 98.31M | 118.99M | 23.37B | 12.73M | | Gross Margin (ttm): | 30.03% | -2.31% | -1.31% | 76.36% | 51.15% | | EBITDA (ttm): | -13.56M | -41.20M | -16.09M | 7.81B | -1.76M | | Oper Margins (ttm): | -907.07% | -48.68% | -19.54% | 26.63% | -19.80% | | Net Income (ttm): | -9.10M | -49.19M | -11.27M | 8.05B | N/A | | EPS (ttm): | -0.873 | -1.185 | 1.617 | 3.808 | N/A | | P/E (ttm): | N/A | N/A | 6.15 | 9.82 | 23.95 | | PEG (5 yr expected): | N/A | N/A | 0.22 | 2.26 | 1.38 | | P/S (ttm): | 19.21 | 7.08 | 8.23 | 3.36 | 3.47 |
|
| ALNY = Alnylam Pharmaceuticals, Inc. | | ISIS = Isis Pharmaceuticals, Inc. | | MRK = Merck & Co. Inc. | | Industry = Diagnostic Substances | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.80 | 2.24% | 56.48B | 12.17 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 50.07 | 1.25% | 14.48B | 16.76 | | Genzyme Corp. | GENZ | 48.78 | 1.20% | 12.95B | 27.81 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 42.83 | -0.86% | 38.54B | 16.56 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.28 | 0.81% | 9.15B | 1046.53 | | Teva Pharmaceutical Industries Limited | TEVA | 52.91 | 0.84% | 46.61B | 48.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 38.09 | 0.42% | 4.04B | 19.63 | | King Pharmaceuticals Inc. | KG | 11.89 | 1.80% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.25 | -0.92% | 5.58B | 111.96 | | Pfizer Inc. | PFE | 18.30 | 0.44% | 147.67B | 15.20 | | Johnson & Johnson | JNJ | 64.37 | -0.16% | 177.60B | 14.06 | | GlaxoSmithKline plc | GSK | 41.80 | -0.36% | 105.96B | 13.53 | | Sanofi-Aventis | SNY | 39.11 | 1.90% | 102.12B | N/A | | Novartis AG | NVS | 54.21 | 0.58% | 123.12B | 16.23 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.95 | 0.70% | N/A | N/A | | AstraZeneca plc | AZN | 45.54 | -0.11% | 66.03B | 9.14 | | Abbott Laboratories | ABT | 53.34 | -0.45% | 82.50B | 14.45 | | Bristol-Myers Squibb Co. | BMY | 25.78 | 0.04% | 51.07B | 13.34 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | MRK | | 2009: The Year Pharma Learned to Love Itself
Fri, Dec 18 -
at Motley Fool | | • | MRK | | Buy a Company, Get the Plant for Free
Fri, Dec 18 -
at Motley Fool | | • | MRK | | The Only Asset Worth Owning Today
Fri, Dec 18 -
at Motley Fool | | • | MRK | | ABT Seeks Simcor Label Expansion
Fri, Dec 18 -
Zacks.com | | • | MRK | | Anadys Drug Meets Key Study Goals
Fri, Dec 18 -
Zacks.com | | • | MRK | | UPDATE - European experts recommend Amgen, Glaxo bone drug
Fri, Dec 18 -
at Reuters | | • | MRK | | Ariad rounds out phase 3 cancer study
Fri, Dec 18 -
at bizjournals.com | | • | ISIS | | These 5 Underdogs Are No Dogs
Thu, Dec 17 -
at Motley Fool | | • | ALNY | | Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology
Thu, Dec 17 -
Business Wire | | • | ALNY | | Isis and Alnylam Announce Notice of Allowance for New U.S. Patent Application Broadly Covering RNAi Therapeutics
Tue, Dec 15 -
Business Wire | | • | ISIS | | Making and Breaking Biotech Deals
Mon, Dec 14 -
at Seeking Alpha | | • | ISIS | | 4-Star Stocks Poised to Pop: Isis Pharmaceuticals
Fri, Dec 11 -
at Motley Fool | | • | ISIS | | 3 Stocks Hitting Low Notes
Wed, Dec 9 -
at Motley Fool | | • | ALNY | | Regulus Therapeutics Inc. presents: "MicroRNA: The Year in Review and a Look Ahead"
Wed, Dec 9 -
Business Wire | | • | ALNY | | Alnylam to Webcast Presentation at Piper Jaffray 21st Annual Health Care Conference
Tue, Nov 24 -
Business Wire | | • | ALNY | | Alnylam Pharma downgraded by Roth Capital
Tue, Nov 24 -
Briefing.com | | | All Headlines for these symbols... |
|
|
|
0.20% Nasdaq 
0.15 (7.17%) 
Competitors
